-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of February 14, Jincheng Pharmaceutical announced that its wholly-owned subsidiary Shandong Jincheng Bio was inquired on the CDE "Original and Auxiliary Package Registration Information" publicity platform and learned that the registration application for "posaconazole" API submitted by it was approved by the CDE.
.
Posaconazole is a second-generation triazole antifungal drug mainly used to prevent invasive Aspergillus and Candida infections
.
Posaconazole preparations include oral suspensions, enteric-coated tablets and injections, all of which have been approved for marketing in China
At present, through the original auxiliary package registration information platform of the State Food and Drug Administration, the posaconazole APIs of 2 companies including Jincheng Bio have been approved